Welcome to the Cancer Research Institute at Queen's University
The Queen's Cancer Research Institute (QCRI) was established in 2001. The open concept building was designed to accommodate three major cancer research groups already located at the University and to provide space for new cancer research initiatives. The four-storey Institute is directly connected to previously existing cancer research laboratories in the adjacent Health Sciences building, providing a total of approximately 60,000 sq.ft. of dedicated research space. Research in the Institute extends from population studies of cancer etiology, through tumor biology and clinical trials, to outcomes and health services research. The Institute is committed to fostering transdisciplinary investigation of areas of cancer control that lie at the interface between fundamental, clinical and population research.
The three divisions of the Institute are presently populated by approximately 250 faculty, graduate and post-doctoral trainees and support staff. Opportunities for graduate and post-doctoral training are offered in partnership with several departments at the University, including: Anatomy & Cell Biology, Biochemistry, Community Health & Epidemiology, Mathematics & Statistics, Microbiology & Immunology, Oncology, Pathology & Molecular Medicine, Pharmacology & Toxicology and the Queen's School of Policy Studies. The Institute also operates a training program in transdisciplinary cancer research, supported by the Terry Fox Foundation in partnership with the Canadian Institutes of Health Research, that is tailored to meet the needs of graduate and post-doctoral trainees from a wide range of disciplines.
Cancer Biology and Genetics (CBG)
Roger Deeley, Division Director
The Division of Cancer Biology and Genetics includes basic and clinician scientists from the Departments of Biochemistry, Pathology & Molecular Medicine, Oncology, Microbiology & Immunology and Pharmacology & Toxicology, all of whom are involved in laboratory based fundamental and translational research in cancer biology and genetics. A major strength of the CBG division lies in identification and characterization of novel genes encoding proteins involved in malignant transformation, tumour growth and progression to metastatic and drug resistant disease. These include receptor tyrosine kinases, transcription factors, drug transporters and drug metabolizing enzymes.
Cancer Clinical Trials (CCT)
Ralph Meyer, Division Director
CCT houses the Canadian Cancer Society Research Institute's NCIC Clinical Trials Group (NCIC CTG), a national research group that develops, conducts, and analyzes multi-institutional trials of cancer therapy. Over 60 institutions involved in cancer care in Canada and elsewhere participate in CTG studies. In addition, the CTG participates in international trials in North America, Europe and Australia. The CTG has two main areas of study: investigational new drugs; and comparative randomized (phase III) trials. The CTG's role in investigational new drug trials is to provide a centralized focus of knowledge, expertise, and experience to help Canadian investigators compete successfully for access to promising and scientifically interesting new agents. The Phase III program develops and conducts randomized trials across the spectrum of adult malignancies. Investigators at the CTG have played lead roles in the development of new methodology for study designs, assessment of response, and toxicity, which have become accepted internationally. In addition, it provides the organizational mechanism for collaboration in international trials.
Cancer Care and Epidemiology (CCE)
Micheal Brundage, Division Director
The CCE is a multidisciplinary health services research group with a mandate to study all aspects of cancer care delivery and cancer epidemiology. It includes principal investigators from the disciplines of Oncology, Cognitive Psychology, Clinical Epidemiology, Biostatistics, Health Economics, and Epidemiology. Research within the Division is pursued under four domains. The Information and Decision Support Group focuses on improving doctor-patient communication and on patient preferences and education. The Treatment and Outcomes Group provides quantitative information on the development and implementation of medical management policies and investigates geographic variations in the management and outcome of cancer. A Health Policy Group focuses on the structure of the cancer system and its influence on the effectiveness and efficiency of treatment programs. The Cancer Etiology Group conducts population-based studies of environmental risk factors for cancer.
The Queen's University, Terry Fox Foundation Training Program in Transdisciplinary Cancer Research in partnership with CIHR
The Terry Fox Foundation Training Program in Transdisciplinary Cancer Research in partnership with CIHR was established at Queen's University to produce future leaders in translational cancer research in Canada. This program provides young investigators, including graduate students, post-doctoral and post-MD fellows, with training and hands-on experience in transdisciplinary research while broadening their perspective on the cancer problem. The Program welcomes basic science, applied clinical, population health and health services trainees and will offer each of these groups a training program specifically tailored to their background and previous educational path.